Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.

Date publication

janvier 2022

Journal

BMC infectious diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Dr HABERSETZER François , Dr MINELLO Anne

Tous les auteurs :
Pageaux GP, Nzinga CL, Ganne N, Samuel D, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, de Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Riachi G, Alric L, Gelu-Simeon M, Minello A, Gournay J, Geist C, Tran A, Abergel A, Portal I, d'Alteroche L, Raffi F, Fontaine H, Carrat F, Pol S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35086481

Résumé

In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatment or not with direct antiviral agents from the French ANRS CO22 HEPATHER cohort.

Mots clés

Decompensated cirrhosis, Direst-acting antiviral agents, Hepatitis C virus, Hepatocellular carcinoma, Survival, Sustained virological response

Référence

BMC Infect Dis. 2022 Jan 27;22(1):94